133 related articles for article (PubMed ID: 1353709)
1. Enzyme-linked immunosorbent assay of c-erbB-2 oncoprotein in breast cancer.
Nugent A; McDermott E; Duffy K; O'Higgins N; Fennelly JJ; Duffy MJ
Clin Chem; 1992 Aug; 38(8 Pt 1):1471-4. PubMed ID: 1353709
[TBL] [Abstract][Full Text] [Related]
2. Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer.
Nugent A; Gallagher J; Dolan J; O'Higgins N; Duffy MJ
Ann Clin Biochem; 1994 Mar; 31 ( Pt 2)():171-3. PubMed ID: 7914719
[TBL] [Abstract][Full Text] [Related]
3. Measurement of erbB-2 oncoprotein in human breast cancers by ELISA.
Nugent A; McDermott E; O'Higgins N; Fennelly JJ; Duffy MJ
Biochem Soc Trans; 1992 Feb; 20(1):82S. PubMed ID: 1353039
[No Abstract] [Full Text] [Related]
4. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.
Gusterson BA; Gelber RD; Goldhirsch A; Price KN; Säve-Söderborgh J; Anbazhagan R; Styles J; Rudenstam CM; Golouh R; Reed R
J Clin Oncol; 1992 Jul; 10(7):1049-56. PubMed ID: 1351538
[TBL] [Abstract][Full Text] [Related]
5. Determination of c-erbB-2 protein in primary breast cancer tissue extract using an enzyme immunoassay.
Watanabe T; Fukutomi T; Tsuda H; Adachi I; Nanasawa T; Yamamoto H; Abe K
Jpn J Cancer Res; 1993 Dec; 84(12):1279-86. PubMed ID: 7904987
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of co-expression of c-erbB-2 oncoprotein and epidermal growth factor receptor in breast cancer patients.
Osaki A; Toi M; Yamada H; Kawami H; Kuroi K; Toge T
Am J Surg; 1992 Oct; 164(4):323-6. PubMed ID: 1357997
[TBL] [Abstract][Full Text] [Related]
8. c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry.
Dawkins HJ; Robbins PD; Sarna M; Carrello S; Harvey JM; Sterrett GF
Pathology; 1993 Apr; 25(2):124-32. PubMed ID: 8103591
[TBL] [Abstract][Full Text] [Related]
9. Human breast cancer: prognostic significance of the c-erbB-2 oncoprotein compared with epidermal growth factor receptor, DNA ploidy, and conventional pathologic features.
Gasparini G; Gullick WJ; Bevilacqua P; Sainsbury JR; Meli S; Boracchi P; Testolin A; La Malfa G; Pozza F
J Clin Oncol; 1992 May; 10(5):686-95. PubMed ID: 1349034
[TBL] [Abstract][Full Text] [Related]
10. Relevance of p185 HER-2/neu oncoprotein quantification in human primary breast carcinoma.
Bermont L; Algros MP; Baron MH; Adessi GL
Breast Cancer Res Treat; 2000 Sep; 63(2):163-9. PubMed ID: 11097092
[TBL] [Abstract][Full Text] [Related]
11. Level of c-erbB-2 oncoprotein in the homogenate of malignant and benign breast tumor samples.
Regidor PA; Callies R; Schindler AE
Eur J Gynaecol Oncol; 1995; 16(2):130-7. PubMed ID: 7641740
[TBL] [Abstract][Full Text] [Related]
12. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
13. The c-erbB-2 protein in primary and metastatic breast carcinomas.
Nesland JM; Ottestad L; Børresen AL; Tvedt KE; Holm R; Heikkilä R; Tveit K
Ultrastruct Pathol; 1991; 15(3):281-9. PubMed ID: 1678562
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of cathepsin D and c-erbB-2 oncoprotein in a subgroup of node-negative breast cancer patients with low histological grade tumors.
Gaci Z; Bouin-Pineau MH; Gaci M; Daban A; Ingrand P; Métayé T
Int J Oncol; 2001 Apr; 18(4):793-800. PubMed ID: 11251176
[TBL] [Abstract][Full Text] [Related]
15. Elevated erbB-2 oncoprotein levels in preoperative and follow-up serum samples define an aggressive disease course in patients with breast cancer.
Isola JJ; Holli K; Oksa H; Teramoto Y; Kallioniemi OP
Cancer; 1994 Feb; 73(3):652-8. PubMed ID: 7905363
[TBL] [Abstract][Full Text] [Related]
16. c-erbB-2 positive breast tumours behave more aggressively in the first years after diagnosis.
Schroeter CA; De Potter CR; Rathsmann K; Willighagen RG; Greep JC
Br J Cancer; 1992 Oct; 66(4):728-34. PubMed ID: 1358163
[TBL] [Abstract][Full Text] [Related]
17. Internal mammary nodal status is a more reliable prognostic factor than DNA ploidy and c-erb B-2 expression in patients with breast cancer.
Noguchi M; Koyasaki N; Ohta N; Kitagawa H; Earashi M; Thomas M; Miyazaki I; Mizukami Y
Arch Surg; 1993 Feb; 128(2):242-6. PubMed ID: 8094282
[TBL] [Abstract][Full Text] [Related]
18. C-erbB-2 oncoprotein expression versus internal mammary lymph node metastases as additional prognostic factors in patients with axillary lymph node-positive breast cancer.
Noguchi M; Koyasaki N; Ohta N; Kitagawa H; Earashi M; Thomas M; Miyazaki I; Mizukami Y
Cancer; 1992 Jun; 69(12):2953-60. PubMed ID: 1350504
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-3 and c-erbB-2 protein expression in node-negative breast carcinoma--an immunocytochemical study.
Gasparini G; Gullick WJ; Maluta S; Dalla Palma P; Caffo O; Leonardi E; Boracchi P; Pozza F; Lemoine NR; Bevilacqua P
Eur J Cancer; 1994; 30A(1):16-22. PubMed ID: 7908213
[TBL] [Abstract][Full Text] [Related]
20. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer.
Isola J; Weitz S; Visakorpi T; Holli K; Shea R; Khabbaz N; Kallioniemi OP
J Clin Oncol; 1993 Jan; 11(1):36-43. PubMed ID: 8093367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
